Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Thomas S. Uldrick"'
Autor:
Robert Yarchoan, Kathryn Lurain, Denise Whitby, Ramya Ramaswami, Mark N. Polizzotto, Anaida Widell, Thomas S. Uldrick, Jomy M. George, Seth M. Steinberg, Priscila H. Goncalves, Kathleen M. Wyvill
Publikováno v:
Clin Cancer Res
Purpose:Kaposi sarcoma (KS) is caused by Kaposi sarcoma herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8). KS, which develops most frequently among people with HIV, is generally treated with chemotherapy, but these drugs have acute and cu
Autor:
Suzanne George, Caroline Schenkel, S. Percy Ivy, Edward S. Kim, Gwynn Ison, Mark Stewart, Patricia A. Spears, Diana Merino Vega, Richard L. Schilsky, Thomas S. Uldrick, Alexander I. Spira, James L. Wade, Andrea Denicoff, Allison Magnuson, Raymond P. Perez, Suanna S. Bruinooge, R. Donald Harvey, Julia A. Beaver, William D. Tap
Publikováno v:
Clinical Cancer Research. 27:2394-2399
Purpose: Restrictive clinical trial eligibility criteria (EC) limit the number of patients who can enroll and potentially benefit from protocol-driven, investigational treatment plans and reduce the generalizability of trial results to the broader po
Autor:
George Anthony Komatsoulis, Suanna S. Bruinooge, Whitney Rhodes, Gwynn Ison, Richard L. Schilsky, Edward J. Stepanski, Elizabeth Garrett-Mayer, Robert S. Miller, Wendy S. Rubinstein, Edward S. Kim, Sean Khozin, Caroline Schenkel, R. Donald Harvey, Thomas S. Uldrick, Li Chen
Publikováno v:
Clinical Cancer Research. 27:2430-2434
Purpose: Cancer clinical trials often accrue slowly or miss enrollment targets. Strict eligibility criteria are a major reason. Restrictive criteria also limit opportunities for patient participation while compromising external validity of trial resu
Autor:
Kathryn Finch Mileham, Cassadie Moravek, Andrew S. Kennedy, Thomas S. Uldrick, E. Claire Dees, Caroline Schenkel, Scot Ebbinghaus, S. Percy Ivy, Jamie Renee Brewer, Atiqur Rahman, R. Donald Harvey, Vishal Bhatnagar, Elizabeth Ness
Publikováno v:
Clin Cancer Res
Purpose: Washout periods and concomitant medication exclusions are common in cancer clinical trial protocols. These exclusion criteria are often applied inconsistently and without evidence to justify their use. The authors sought to determine how was
Autor:
Hao-Wei Wang, Pamela L. Wolters, Kathryn Lurain, Stefania Pittaluga, Thomas S. Uldrick, Constance M. Yuan, Jomy M. George, Elaine S. Jaffe, Anaida Widell, Ramya Ramaswami, Priscila H. Goncalves, Richard F. Little, Mary Anne Tamula, Robert Yarchoan, Staci Martin, Mark N. Polizzotto, Seth M. Steinberg
Publikováno v:
Blood
Autor:
R Mangusan, R. Ramaswami, Thomas S. Uldrick, Romin Roshan, Kathryn Lurain, Denise Whitby, Anaida Widell, R Yarchoan, J. M Ziegelbauer, I Ekwede, L. T Krug
Publikováno v:
Hematological Oncology. 39
Autor:
Kathryn Lurain, Ramya Ramaswami, Stefania Pittaluga, Elaine S. Jaffe, Jomy M. George, Seth M. Steinberg, Mark N. Polizzotto, Priscila H. Goncalves, Richard F. Little, Vickie Marshall, Adam Rupert, Hao-Wei Wang, Ralph Mangusan, Robert Yarchoan, Kirsta Waldon, Denise Whitby, Thomas S. Uldrick, Irene Ekwede, Anaida Widell
Publikováno v:
Blood Adv
Kaposi sarcoma (KS)-associated herpesvirus (KSHV)–associated multicentric Castleman disease (MCD) is a relapsing and remitting systemic lymphoproliferative disorder characterized by severe inflammatory symptoms most common among people living with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::146ec5c676903f36389d85eb63f83d20
https://europepmc.org/articles/PMC7993110/
https://europepmc.org/articles/PMC7993110/
Autor:
Priscila H. Goncalves, Thomas S. Uldrick, Mark N. Polizzotto, Ramya Ramaswami, Denise Whitby, Seth M. Steinberg, Giovanna Tosato, Anaida Widell, Robert Yarchoan, William D. Figg, Kathryn Lurain, Kathleen M. Wyvill
Publikováno v:
Clin Cancer Res
Purpose: VEGF-A is important in the pathogenesis of Kaposi sarcoma, and bevacizumab has a response rate of 31%. We explored the combination of bevacizumab with liposomal doxorubicin in patients with Kaposi sarcoma. Patients and Methods: Patients with
Autor:
Hao-Wei Wang, Richard F. Ambinder, Thomas S. Uldrick, Anaida Widell, Ralph Mangusan, Irene Ekwede, Martin A. Cheever, Robert Yarchoan, James L. Gulley, Kathryn Lurain, Ramya Ramaswami, Priscila H. Goncalves, Jomy M. George
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundNon-Hodgkin’s lymphoma (NHL) is currently the most common malignancy among people living with HIV (PLWH) in the USA. NHL in PLWH is more frequently associated with oncogenic viruses than NHL in immunocompetent individuals and is generally
Publikováno v:
Curr HIV/AIDS Rep
PURPOSE OF REVIEW: Immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1) pathway are a class of anti-cancer immunotherapy agents changing treatment paradigms of many cancers that occur at higher rates in people living with HIV (PL